StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
542 Study Matches

A082002 Randomized Phase II/III of immunotherapy with or without SBRT PD-L1 negative NSCLC (22-026)

To assess if SBRT improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage NSCLC patients with PD-L1 TPS <1% who receive immunotherapy with or without chemotherapy

We are asking you to take part in a research study. This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.

Yes
 

Joseph Miccio
psci-cto@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04929041
SITE00001209
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years
No prior systemic chemotherapy or immunotherapy for advanced NSCLC
Not pregnant and not nursing
No known history of Hepatitis B or Hepatitis C
Platelet Count ≥ 100,000/mm3

Exclusion Criteria:
Live vaccine within 30 days prior to registration
Current pneumonitis or history of non-infectious pneumonitis that required steroids
Prior allogeneic tissue/solid organ transplant.
Age < 18 years
ECOG Performance Status over 3
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Livestreaming, Content Creation, and Playing and Learning Online

This study surveys how different viewers, livestreamers and content creators learn and engage online. We are recruiting people who view or create content on livestreaming platforms such as Twitch, YouTube or Mixer (past or present). This study involves filling out a survey which should take 15-20 minutes to complete. Participants will be entered into a drawing to win one of 20 $75 e-gift cards for their participation.

No
 

Gabriela Richard
G. Richard - at gamingstudy@psu.edu
Non-PSU Site
 

All
All
This study is also accepting healthy volunteers
STUDY00015114
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
people who livestream
people who watch livestreams
aged 13 or older (if not yet legally adults, with parental/guardian permission)
online content creators
gamers or esports viewers

Exclusion Criteria:
under 13 years of age
cannot read, communicate or provide consent in English
does not livestream or watch livestreams or create content online
if a minor, does not have parental/legal guardian permission
Education
I'm interested
Share via email

Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (PSCI# 21-207) (NRG-HN009)

The purpose of this study is to compare two usual treatment approaches to your head and neck cancer: high-dose cisplatin given every 3 weeks with radiation to low-dose cisplatin given weekly with radiation. The first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks. The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach. There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.

he first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks.The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach.There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.

Yes
 

Sean Mahase
PSCI-CTO@pennstatehealth.psu.edu
Radiation Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05050162
SITE00001120
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to registration
Age ≥ 18
Zubrod (ECOG) performance status of 0-1 within 14 days prior to registration
Adequate hematologic function within 30 days prior to registration
Adequate renal function within 30 days prior to registration defined as calculated creatinine clearance (CrCl) ≥ 50 mL/min by the Cockcroft-Gault formula

Exclusion Criteria:
Patients with oral cavity cancer, nasopharynx cancer, or p16-negative cancer of unknown primary (CUP);
Definitive clinical or radiologic evidence of distant metastatic disease
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Pregnancy and individuals unwilling to discontinue nursing
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Future of Construction Workplace Health Monitoring

This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for construction workplace health monitoring.

There will be one in person visit, you will be asked to sit still for 3 minutes and then move your skin for another 3 minutes.

Yes
 

Huanyu Cheng
Huanyu Cheng - at huc24@psu.edu or 814-863-5945
Engineering Science and Mechanics (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020934
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
no existing skin conditions or open wounds, or other disorders that make them have altered temperature responses.
be over 18 years old.
must understand English.
from Penn State, University Park

Exclusion Criteria:
have existing skin conditions or open wounds, or other disorders that make them have altered temperature responses.
cannot understand English
under 18 years old
Men's Health, Women's Health
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

This is a drug study that will examine if inhaled treprostinil is save and effective in people diagnosed with Progressive Pulmonary Fibrosis.

You will be required to attend 8 in-person visits at the Hershey Medical Center over the span of approximately one year. During the study you will have physical examinations, complete questionnaires, review your medical history and current medications, have vital signs and ECGs taken, have blood tests performed, complete pulmonary function testing, and potentially have a high resolution CT scan done. You will take the inhaled treprostinil or placebo daily at home throughout the study.

600

Yes
 

Rebecca Bascom
Tim Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05943535
STUDY00023883
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Pulmonary Fibrosis
Evidence of progression of pulmonary fibrosis in the last 24 months

Exclusion Criteria:
Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
Evidence of obstructive pulmonary disease
Concomitant use of both nintedanib and pirfenidone is not permitted
Received any PAH-approved therapy in last 60 days
Receiving >10 L/min of oxygen supplementation
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

BCC018: A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

This study is being done to learn if it is safe to add naxitamab to standard therapy during the Induction phase of care for patients with newly diagnosed high-risk neuroblastoma. Naxitmab is an immunotherapy agent which trains your immune system to target your tumor in a more specific way than chemotherapy does.

This study has 3 phases- screening, treatment, and follow up. If you join the study, during screening we will test a sample of your tumor along with your blood. The tumor sample will be obtained at the same time as you are having surgery or a biopsy. Other testing will be done to make sure you are eligible to receive treatment. If you are eligible for treatment, you will receive five 21 day cycles of anti-cancer medication (induction chemotherapy) along with naxitamab. You will have to stay in the hospital to receive this treatment for at least 6 days of each 21 day cycle. If your screening testing also shows a certain genetic change in your tumor, we may also add a medication that is targeted at that change. If your tumor does not respond adequately to the initial cycles, we may give up to three additional 21 day cycles of chemotherapy with naxitamab. You will also have procedures at certain timepoints during induction that are standard of care for your tumor. These include collecting stem cells for use later in your therapy after Cycle 2. After Cycle 4, you will have surgery to remove as much of the tumor as possible. The treatment phase will last about 8 months, after which you will be in follow up. During your time on the study, we will ask to collect research samples of blood, bone marrow, and tumor. We will be monitoring your progress and health throughout your time on treatment and in follow up.

Yes
 

Lisa McGregor
Suzanne Treadway - at streadway@pennstateheath.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05489887
STUDY00023083
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of high-risk neuroblastoma or ganglioneuroblastoma
≤ 21 years of age at initial diagnosis and > 12 months of age at time of enrollment

Exclusion Criteria:
< 1 year of age
Receiving any investigational drug
Cancer
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The opioid epidemic among Pennsylvania immigrants: Implications for treatment practices

We plan to interview PA immigrants who have first-hand experience with opioid abuse or who have friends/family/neighbors with opioid abuse experiences. The goal is to highlight areas for improvement, regarding access to treatment and quality of treatment for immigrants. We hypothesize that immigrant status uniquely impacts this group and their rehabilitation journeys, but this has not yet been studied.

There will be one semi-structured, qualitative interview over Zoom, for about 45 minutes. Interviews may be in-person if there is no Zoom access.

$75.00 gift card

No
 

Abigail Akande
Abigail Akande - at aoa29@psu.edu
Social and Behavioral Sciences (ABINGTON)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021287
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Immigrant (non-citizen)
PA resident
18 years of age and older
Experience with opioid abuse
Friend or family member with opioid abuse experience

Exclusion Criteria:
Reside outside of PA
U.S. citizen
Below 18 years of age
No opioid abuse experience
diagnosis of an intellectual/developmental disability
Addiction & Substance Abuse, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Digital tools for assessment of motor functions and falls in ALS

This is a 48-week, two arm study that incorporates digital tools for assessing motor function in amyotrophic lateral sclerosis (ALS) and healthy controls.During the study, neck- and wrist-worn “activity sensors” (PAMSys, BioSensics, Newton, MA) will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. They will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. We will explore whether sensor-based functional changes are sensitive to self-reported changes over the length of the study.

During the study, neck- and wrist-worn “activity sensors” (PAMSys, BioSensics, Newton, MA) will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. They will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet.Subjects will be required to visit the study site around the time of 5 consecutive standard ALS clinic appointments.The research study will last approximately 48 weeks.

$240

Yes
 

Andrew Geronimo
Wint Nandar - at wnandar@pennstatehealth.psu.edu
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT05271435
STUDY00013892
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA), or a control subject
18 years of age or older
Walking with or without mobility support (such as a cane or walker)
Fluent in written and spoken English

Exclusion Criteria:
Neurological or orthopedic problems independent of inclusionary diagnosis that affects gait
Pregnant or nursing woman
Prisoner or institutionalized individuals
Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Neurology
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects

Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.

You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.

Yes
 

Andrea Zaenglein
Dermatology Clinical Trials - at dermatologyclinicaltrial@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05889182
SITE00001422
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
12 years of age and older
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash

Exclusion Criteria:
Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded. - Study coordinator will discuss
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

User experience with smart devices

This study investigates users’ experience with smart devices. This study makes further implications for designing more user-friendly devices for better user experience. We aim to make such contributions by answering these questions:1.How do users interact with smart devices?2.What challenges do users face when using smart devices?3.What strategies do users apply to adapt themselves to smart devices?4.What service do smart device producers provide for users to get a better user experience?5.When does user experience break down when interacting with smart devices?The study methods are social media data analysis, interview, survey, and focus group.

Yes
 

Yubo Kou
Yao Lyu - at yml5549@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014519
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or elder
all genders included
have prior experience with smart devices

Exclusion Criteria:
younger than 18 years old
all vulnerable populations, such as pregnant women, cognitive impaired adults, and prisoners.
no prior experience with smart device
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Use of the Frequen-ZZZ Sleep Pad to Increase Restorative Sleep: A Proof-of-Concept Study

This research is a small, 8wk clinical trial testing the potential effects of an investigational device, Frequen-ZZZ/Sleepergize Sleep Pad, on the sleep of adults 40-65 years old. We aim to determine whether sleeping with the Sleep Pad, which creates an electromagnetic field around the sleeper, has an improving effect on sleep. Sleep will be primarily measured using a non-invasive clinical standard method, called polysomnography (PSG), for 6 separate nights in the personal residence of participants. Sleep will also be measured both day and night with a watch-like device that measures activity, and with surveys. We will look for changes in sleep quality, in sleep duration, and in the way that sleep is organized by the body. We will also measure changes in inflammation, which is related to sleep, from 3 blood samples collected during the study. There are 15-17 in-person appointments across the course of the study. With the data, we hope to also evaluate the feasibility and effect sizes of this non-pharmacological intervention to inform future research, and we plan to use data in support of a future FDA application for the device.

Participation involves sleeping with the investigational device, 6 separate nights of sleep monitoring in your home with standard equipment that is used in clinical settings, 3 blood draws, surveys, and wearing an activity watch, all over the course of an ~8wk participation period. There are 15-17 in-person appointments and about 15 active hours of engagement involved in the study.

$3,000.

Yes
 

Anne-Marie Chang
Anne-Marie Chang - at sleeppad@psu.edu
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT05908344
STUDY00020435
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
40-65 years of age (inclusive)
At least some Insomnia symptoms
Living without assistance and able to sign own informed consent
Not a nocturnal shift or rotating shift-worker
English speaker/reader

Exclusion Criteria:
Current smoker
Diagnosed with a sleep disorder
Pacemaker
Pregnant, breast-feeding, or planning to become pregnant
Taking prescribed medication or therapy for sleep
Men's Health, Sleep Management, Women's Health
Experimental device
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

In Alexa, we Trust. Or do we ? : A Case Study of Privacy Policies of Amazon's Intelligent Voice Assistant

Trying to understand how humans alter their behavior when presented with new information regarding privacy rules.

No
 

Sanjana Gautam
Sanjana Gautam - at sqg5699@psu.edu or 814-867-5787
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014700
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older
Must own a smart home device

Exclusion Criteria:
Most not be younger than 18 years of age
I'm interested
Share via email

Factors that contribute to use or abandonment of high-tech AAC among parents and direct supports

The study will survey parents, caregivers, and direct care professionals who support children and adults with intellectual disability, autism and limited vocal speech. The survey will ask questions specifically related to participants' experiences supporting an individual with communication needs. The study will gather information on factors that contribute to the use of high-tech AAC as a mode of communication compared to other types of AAC.

Participants should click on the link below to participate. Participants will answer questions about their experiences in supporting children and adults with intellectual disabilities, autism and limited vocal speech. The questions will relate specifically to supporting their communication needs. The survey will take about 10 minutes to complete, and participants will have an option to provide additional information which could take another 10 minutes to complete.https://pennstate.qualtrics.com/jfe/form/SV_0MuXHc2fLOWVfy6

Participants can choose to be entered into a monthly drawing to receive a $25 gift card.

No
 

Erin Edwards
Erin Edwards - at eedwards@pennstatehealth.psu.edu or 717-531-0003, ext=285976
Psychiatry and Behavioral Health (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00024243
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1.Parent, guardian or unpaid caregiver or paid support professional who supports (currently or within the past year) an individual with autism, intellectual disability and limited functional vocal speech
2.Must older than 18 years of age
3.English-speaking

Exclusion Criteria:
1.Is not a parent, guardian or unpaid caregiver or paid support professional who supports an individual with autism, intellectual disability and limited functional vocal speech
2.Has not supported an individual with autism, intellectual disability and limited functional vocal speech in the past year
3.Under the age of 18
4.Non-English speaking
Mental & Behavioral Health
Survey(s)
I'm interested
Share via email

Translational Studies on Electronic Cigarette-derived Oxidants and their Long-term Cardiopulmonary Effects

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting COPD

You will be asked to reduce your cigarette smoking and use study-provided e-cigarettes for 3 months. You will be asked to attend 2 in-person visits at the Hershey Medical Center and participate in 4 telephone visits. Throughout the study you will be asked to complete questionnaires, have heart rate, blood pressure and pulse oximetry taken, electrocardiograms (ECGs), height and weight measured, provide medical history, perform pulmonary function tests, complete a 6-minute walk, have your exhaled carbon monoxide measured, provide urine specimen and have blood drawn.

Yes
 

Rebecca Bascom
Timothy Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05239793
STUDY00015514
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 21-74
mild-moderate COPD
current smoker

Exclusion Criteria:
actively changing smoking behavior
current use of other tobacco products
allergic to vegetable glycerin and/or propylene glycol
chronic drug and/or alcohol abuse
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Lung Disease & Asthma
Approved device(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Environmental Exposure and ALS

We are hoping to learn more about the relationship between environmental exposures and developing ALS (Amyotrophic lateral sclerosis - Lou Gehrig’s Disease). Our focus will be on heavy metal and other potential exposures that might occur throughout life at home, in the workplace, and during military service, as examples. Study participants will attend a single study visit to provide information about environmental exposure and to donate blood and toenail clippings.

- Attend a single study visit lasting 1-2 hours- Informed consent- Complete environmental exposure questionnaire- Blood sample collection- Collection of toenail clippings

$20

Yes
 

Zachary Simmons
Heidi Runk - at nervemuscle@pennstatehealth.psu.edu or 717-531-8257
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00026301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 years or older
ALS diagnosis (for cases)
Cognitive ability to consent or legally authorized represenative

Exclusion Criteria:
Diagnosis of any other neurodegenerative condition
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding the factors affecting job satisfaction and unemployment in the USA.

This study will assess the various factors that influence job satisfaction, including salary, benefits, work-life balance, work environment, job security, and opportunities for advancement. It will also aim to measure the main causes for unemployment and the impact on general well being.

Complete an electronic survey which will take about 20 minutes on average

No
 

Prabhani Kuruppumullage Don
Prabhani Kuruppumullage Don - at pxk919@psu.edu or 814-863-3193
Statistics (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022901
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
residing in USA

Exclusion Criteria:
less than 18 years old
residing outside USA
Not applicable
I'm interested
Share via email

Linking brain network dynamics to smoking-related behavior

Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.

There will be two in-person visits, both will involve completion of computerized questionnaires and one will involve completing and MRI scan

175

Yes
 

Stephen Wilson
Stephen Wilson - at sjw42@psu.edu or 814-867-2333
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05572671
STUDY00020857
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Smoke cigarettes
Age 21-65

Exclusion Criteria:
Ineligible for MRI scan
Claustrophobic
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Mental & Behavioral Health
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

School Choice: Factors in Making a Choice and the Impact of Economics

The purpose of this study is to communicate with decision makers (parents and guardians) to identify the processes and considerations used when seeking and determining information relative to school choice. This study will examine those factors and see if there is equality among socio economic groups.

No
 

Michelle Cook
Michelle Cook - at mxc845@psu.edu
Curriculum and Instruction (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00008131
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
parent
guardian
child in elementary / middle school
live in or around a low income community

Exclusion Criteria:
no children in school
not a parent or guardian
I'm interested
Share via email

BCC017: Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG)

This study is being done to learn if a vaccine made in the laboratory from your tumor and your immune cells is safe to give to you to treat your tumor. It is believed that the body’s immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use your tumor and immune cells from your blood to make a vaccine that we hope will stimulate your T-cells to kill tumor cells and leave your normal cells alone.

You will need routine (standard of care) testing for your tumor, as well as research tests and procedures including further analysis of your tumor sample, generation and review of a personalized genetic report, and procedures to collect certain cells for different infusions and creation of specialized cellular vaccines. You will then be offered and placed on a treatment plan. As a subject in this study you will remain in this study until you complete vaccine therapy as long as you have no disease progression or unless you need to come off study for another reason.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehealth.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04837547
STUDY00023080
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Neuroblastoma that has either returned or has not responded to standard therapies or a diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG).
For Neuroblastoma must be >12 months and ≤ 30 years of age
For DIPG must be ≥ 3 years and ≤ 30 years of age

Exclusion Criteria:
Absence of tumor on biopsy specimen or a diagnosis other than NBL or glioma on biopsy
Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection
Cancer
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Digital assessment of speech and fine motor control in motor neuron disease

This study includes collection of digital speech and fine motor control assessment data at a single study visit. Features extracted from this data will be compared with standard clinical disease outcome measures and also the features derived from control participant data. We will use these comparisons to explore the use of these digital assessments in capturing the range of functional changes that occur in motor neuron disease.

This is a single-session study that measures speech and fine motor function using digital tablet-based assessments. Patients with motor neuron disease and age-matched healthy controls will be enrolled. Sessions take approximately one hour.

$20

Yes
 

Andrew Geronimo
Wint Nandar - at wnandar@pennstatehealth.psu.edu
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06315673
STUDY00024562
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
[Patient Group Only] Diagnosis of ALS, primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA)
[Patient Group Only] at least minimal speech or handwriting ability
[Control Group Only] Possess no neurological or orthopedic problems that affects their speech or handwriting AND age- and sex-matched to the existing patient cohort
18 years of age or older
Fluent in written and spoken English.

Exclusion Criteria:
Neurological or orthopedic problems (independent of their inclusionary diagnosis for the patient group) that affects their speech or handwriting
Pregnant or nursing woman
Prisoner or institutionalized individuals
Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Neurology
Survey(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

BCC021: Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors

The purpose of this study is to evaluate the investigational drug Silmitasertib (CX-4945) (a pill taken by mouth) in combination with chemotherapy drugs standardly used for your tumor type. An investigational drug is one that has not been approved by the U.S. Food &amp; Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.

You will undergo a number of standard tests and research-related procedures before being able to enroll on this study.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehealth.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT06541262
STUDY00025626
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Less than 30 years old at initial diagnosis

Exclusion Criteria:
Currently receiving another investigational drug
Cancer
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Development of Lighting Application Efficacy Measurement Framework

This study seeks to analyze how subjects perceive brightness. For this purpose, separate studies will be conducted in a real setting in the Lighting Lab. In experiment one, subjects will be asked to judge the brightness of projected scenes on a wall two by two in comparison to one another. In experiment two, subjects will be asked to judge the brightness of scenes displayed on a monitor by comparing them to a reference scene, by assigning a value between 0 to 100 to the brightness level.

The experiment will take place in 302 Engineering Unit C. The participants will judge the brightness of displayed scenes on a monitor.

$20 for the current experiment

Yes
 

Parisa Mahmoudzadeh
Parisa Mahmoudzadeh - at parissa@psu.edu
Architectural Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00018894
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
between 18-60 years old
normal or corrected to normal visual acuity (participants need to have their prescription glasses or contact lenses on them during the experiments).

Exclusion Criteria:
under 18 years old or over 60 years old
inability to distinguish certain shades of color
participants without glasses or contact lenses prescribed for their visual acuity
lacking clear visual acuity
Vision & Eyes
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Examining views associated with physical exercise and its connection to diet, social connectivity, and stress reduction: Online Focus Groups

The primary objective of this study is to examine, via online focus groups, the perceptions that are held by potentially-eligible subjects in the PSH DPP program in regard to the importance of physical exercise, particularly within the context of diet, social connectivity, and stress reduction. These perspectives will then be used to help develop, test, and refine additional motivational text messages that can be used in a text messaging intervention. Participants will receive a $25.00 gift card.

No
 

Selena Ortiz
Selena Ortiz - at suo13@psu.edu or 814-863-8041
Health Policy and Administration (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014288
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be at least 18 years old and under age 65
Body Mass Index ≥25 kg/m2 (≥23 kg/m2 if Asian)
Have no previous diagnosis of type 1 or type 2 diabetes
Fluent in English

Exclusion Criteria:
Under 18 years old and over age 65
Body Mass Index <25 kg/m2 (<23 kg/m2if Asian)
Previous diagnosis of type 1 or type 2 diabetes
Not fluent in English
Prevention, Education, Diabetes & Hormones
I'm interested
Share via email

Application of graph theory to both resting-state and task-based fMRI data to uncover brain-behavior relationships related to therapy outcomes in aphasia

This project will use fMRI to examine changes in the brain related to behavioral therapy outcomes in persons with aphasia. We aim to recruit twenty persons with aphasia. Each participant will receive 4 MRI scans. Between scan 1 and scan 2, no therapy will be provided (10 week break). Between scan 2 and scan 3, ten weeks of word finding therapy will be provided. Between scan 3 and scan 4, no therapy will be provided (10 week break). The therapy used is abstract word retrieval training. The results of this project will help inform rehabilitation practices in aphasia.

There will be 4 fMRI scans. After the first and third fMRI scans, there will be an assessment. After the second fMRI scan, there will be 10 weeks of treatment.

$460

Yes
 

Chaleece Sandberg
Chaleece Sandberg - at cws18@psu.edu or 814-863-2006
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03550092
STUDY00009502
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of aphasia
Sustained stroke at least 6 months ago
Right-handed
Native English speaker
Completed at least a high school education

Exclusion Criteria:
History of neurodegenerative disease (e.g., Alzheimer's)
History of other acquired neurological disorder (e.g., TBI)
History of developmental disorder (e.g., autism)
History of psychological disorder (e.g., schizophrenia)
Unsafe to receive MRI (e.g., pacemaker)
Neurology, Language & Linguistics
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Analyzing Student Newspaper Political Coverage

This study involves a content analysis of student newspaper political articles, as well as a survey of student journalists regarding their views about how politics are reported in student media.

No
 

Hans Schmidt
Hans Schmidt - at hcs10@psu.edu or 610-892-1251
Academic Affairs (BRANDYWINE)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00009097
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Journalism student
Involvement on student newspaper
Involvement with other student media

Exclusion Criteria:
No involvement in student journalism
Education
I'm interested
Share via email

Health Apps to Mitigate COVID-19 Risk Survey

With the COVID-19 pandemic affecting everyone’s daily routine, our lives have changed drastically. The health of ourselves, families, friends, and communities is our biggest concern and finding a cure to this problem is still underway The purpose of this survey is to analyze how people are taking control of their health using various health applications forms.

No
 

Rafay Ahmad
Rafay Ahmad - at rqa5302@psu.edu or 814-933-2861
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016969
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years old or old

Exclusion Criteria:
Younger than 18 years old
COVID-19, Education, Mental & Behavioral Health
I'm interested
Share via email

Carvedilol in Metastatic HER-2+ Breast Cancer for Prevention of Cardiac Toxicity (PSCI# 20-135) (S1501)

The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during your cancer treatment. Carvedilol (Coreg®) is a medication that is FDA approved and used to treat congestive heart failure and high blood pressure and is not a new medication. It has been shown in small studies to protect the heart from side effects of chemotherapies such as doxorubicin (Adriamycin®) and trastuzumab (Herceptin®). The effects of carvedilol will be compared to the usual approach. Previously, people who were already taking a beta blocker, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor were able to take part in the study. The study has reached the maximum number of people allowed who are already on those treatments now, so, you must not be taking these types of drugs in order to be part of the study. There will be about 817 people taking part in this study.

The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during your cancer treatment. Carvedilol (Coreg®) is a medication that is FDA approved and used to treat congestive heart failure and high blood pressure and is not a new medication. It has been shown in small studies to protect the heart from side effects of chemotherapies such as doxorubicin (Adriamycin®) and trastuzumab (Herceptin®). The effects of carvedilol will be compared to the usual approach. Previously, people who were already taking a beta blocker, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor were able to take part in the study. The study has reached the maximum number of people allowed who are already on those treatments now, so, you must not be taking these types of drugs in order to be part of the study. There will be about 817 people taking part in this study.

Yes
 

Monali Vasekar
psci-cto@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03418961
SITE00001123
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have a Zubrod Performance Status of 0-2.
Patients must be ≥ 18 years of age.
Patients must have a complete physical examination and medical history within 28 days prior to registration.
Patients must not be dialysis dependent
Patients must be able to swallow tablets.

Exclusion Criteria:
Patients are dialysis dependent.
Patients have uncontrolled asthma.
Patients who are pregnant or nursing
Patients who are unable to swallow tablets.
Patients who do not have adequate hepatic function
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

User Mobility and Graph Learning in Virtual Reality

This study investigates how the interaction affects how well 3D graphs are understood and remembered in virtual reality, and how individual differences in spatial ability affect and interact with memory and understanding.

Yes
 

Alexander Klippel
Mark Simpson - at mbs278@psu.edu
Geography (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007004
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Penn State Affiliation

Exclusion Criteria:
Under age 18
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Coping with it All from Labor to Maternity

The CALM Project is looking to learn how different birthing classes prepare child-bearers for parenthood. Participants attend a free birthing class between their 20th and 37th weeks of pregnancy with their partners and fill out three questionnaires during pregnancy and postpartum. Three months after their baby is born, they are video-recorded interacting with their baby in their home and have their brain scanned using MRI. We aim to understand how different childbirth classes support mothers' well-being and bonding with their babies.

Women are asked to 1.complete 3 self-report questionnaires online during pregnancy and after their baby is born (45 minutes each)2.attend a childbirth preparation class (from a few hours to a 9-week class)3.participate in 2 in-person sessions (1.5 hours each): a videorecording with their baby in the home and a brain scan using MRI at Penn State Hershey Medical Center.

$160 + free birthing class

Yes
 

Heidemarie Laurent
Sandy Rosario - at PRISMLab@psu.edu or 814-867-6482
Human Development and Family Studies (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019138
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Less than 28 weeks pregnant
At least 18 years old
Speaks English

Exclusion Criteria:
MRI contraindications (metal implants, brain injury, etc.)
Pregnancy complications that would prevent you from participating in an online class
Pregnancy & Infertility, Women's Health
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,

Psychological and Biological Determinants of Eating Disorder Pathology in Endurance and Aesthetic Athletes

The purpose of this study is to investigate psychobiological factors that impact the development and manifestation of eating disorder (ED) pathology in elite male and female athletes before and during their competitive season.

The purpose of this voluntary research study is to assess how changes in stress, cognitive flexibility, response inhibition, and reward delay predict the trajectory of eating disorder behaviors and associated side effects of energy deficiency from the off-season compared to the competitive season. Your participation in this study will last approximately the duration of one season of your sport, specifically 4-weeks of data collection prior to season commencement (baseline), 4-weeks of data collection during peak competition season, and 4-weeks of data collection during off-season. The total time spent in the lab will be approximately 10-14 hours. Procedures will occur three times and measurements will be taken twice following baseline measures (once during the peak competition season, once during off-season), if you agree to do so.

$50

Yes
 

Mary Jane De Souza
Ana Carla Salamunes - at whel@psu.edu or 814-863-4488
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018984
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-25 years
A member of a Penn State NCAA Division 1 Sports team, or Penn State affiliated competitive club team, or competitive community sport team
Exercising without any training modifications that reduce training participation.
non-smoker
No serious of chronic health conditions

Exclusion Criteria:
BMI >32kg/m2 or <16.5 kg/m2
Currently a smoker or history of regular smoking (including nicotine products, e-cigarettes, vaping)
Medications influencing metabolic or endocrine factors (e.g., hormonal use in previous 6 months)
Medical instability or history of psychosis
Vasectomy (male) or Hysterectomy or oophorectomy (female)
Men's Health, Food & Nutrition, Women's Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,